Botanix Pharmaceuticals Limited (ASX:BOT)
Australia · Delayed Price · Currency is AUD | Market Cap | 73.45M -90.7% |
| Revenue (ttm) | 21.92M +959.2% |
| Net Income | -88.70M |
| EPS | -0.05 |
| Shares Out | 2.72B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,712,244 |
| Average Volume | 33,885,287 |
| Open | 0.0260 |
| Previous Close | 0.0250 |
| Day's Range | 0.0250 - 0.0270 |
| 52-Week Range | 0.0240 - 0.4700 |
| Beta | 0.83 |
| RSI | 32.12 |
| Earnings Date | May 28, 2026 |
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t... [Read more]
Financial Performance
In fiscal year 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.
Financial StatementsNews
Botanix Pharmaceuticals Earnings Call Transcript: Q3 2026
Sofdra prescriptions and revenue continue to grow, with March 2026 setting a new record. Strong cash position, cost discipline, and a new API supplier are expected to drive future margin expansion and mitigate tariff risks. The platform is well-positioned for additional product launches.
Botanix Pharmaceuticals price target lowered to A$1 from A$2 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Botanix Pharmaceuticals (BXPHF) to A$1 from A$2 and keeps a Buy rating on the shares. The firm cites the ongoing equity raise
Botanix Pharmaceuticals Earnings Call Transcript: H1 2026
Sofdra prescriptions and revenue surged in the first half of FY2026, driven by strong sales force execution and a scalable fulfillment platform. A major capital raise is underway to fund growth, reduce COGS, and support expansion, with profitability targeted as platform efficiencies scale.
Botanix Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue and prescriptions for Sofdra grew strongly, with net revenue up 28% quarter-over-quarter and gross-to-net yield improving to 24%. Sales force expansion and a unique fulfillment platform are driving growth, while cost-saving initiatives and high physician intent to prescribe support a positive outlook.
Botanix Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 saw robust growth in Sofdra prescriptions and net sales, driven by an expanded sales force and strong fulfillment platform. Cost management improved margins and liquidity, with all resources focused on Sofdra's success and further market penetration.
Botanix Pharmaceuticals Earnings Call Transcript: Q4 2025
Q4 FY2025 saw a successful Sofdra launch, with gross sales up to $20.4M and net revenue at $4.3M, driven by rapid prescription growth and high refill rates. The company is well-funded, expanding its sales force, and expects to reach profitability without further capital needs.